PortfoliosLab logoPortfoliosLab logo
DRUG.AX vs. BBUS.AX
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

DRUG.AX vs. BBUS.AX - Performance Comparison

The chart below illustrates the hypothetical performance of a A$10,000 investment in Betashares Global Healthcare Currency Hedged ETF (DRUG.AX) and BetaShares US Equities Strong Bear Currency Hedged Complex ETF (BBUS.AX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, DRUG.AX achieves a 1.49% return, which is significantly higher than BBUS.AX's -15.01% return.


DRUG.AX

1D
1.89%
1M
5.32%
6M
0.23%
YTD
1.49%
1Y
17.07%
3Y*
6.21%
5Y*
4.03%
10Y*

BBUS.AX

1D
3.84%
1M
3.48%
6M
-13.05%
YTD
-15.01%
1Y
593.29%
3Y*
46.26%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

DRUG.AX vs. BBUS.AX - Yearly Performance Comparison


2026 (YTD)20252024202320222021
DRUG.AX
Betashares Global Healthcare Currency Hedged ETF
1.49%11.83%1.82%0.76%-3.68%4.88%
BBUS.AX
BetaShares US Equities Strong Bear Currency Hedged Complex ETF
-15.01%527.35%-34.99%-36.60%44.31%-18.21%

Correlation

The correlation between DRUG.AX and BBUS.AX is -0.30, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.30

Correlation (3Y)
Calculated over the trailing 3-year period

-0.41

Correlation (All Time)
Calculated using the full available price history since Aug 9, 2021

-0.55

Over the past year, the inverse relationship between DRUG.AX and BBUS.AX has weakened: their correlation has moved from -0.55 to -0.30, meaning they move in opposite directions less often than they have historically.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

DRUG.AX vs. BBUS.AX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DRUG.AX
DRUG.AX Risk / Return Rank: 3838
Overall Rank
DRUG.AX Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
DRUG.AX Sortino Ratio Rank: 4343
Sortino Ratio Rank
DRUG.AX Omega Ratio Rank: 3838
Omega Ratio Rank
DRUG.AX Calmar Ratio Rank: 3939
Calmar Ratio Rank
DRUG.AX Martin Ratio Rank: 3333
Martin Ratio Rank

BBUS.AX
BBUS.AX Risk / Return Rank: 8484
Overall Rank
BBUS.AX Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
BBUS.AX Sortino Ratio Rank: 100100
Sortino Ratio Rank
BBUS.AX Omega Ratio Rank: 9999
Omega Ratio Rank
BBUS.AX Calmar Ratio Rank: 9999
Calmar Ratio Rank
BBUS.AX Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DRUG.AX vs. BBUS.AX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Betashares Global Healthcare Currency Hedged ETF (DRUG.AX) and BetaShares US Equities Strong Bear Currency Hedged Complex ETF (BBUS.AX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


DRUG.AXBBUS.AXDifference
Sharpe ratioReturn per unit of total volatility

+0.45

Sortino ratioReturn per unit of downside risk

-35.84

Omega ratioGain probability vs. loss probability

1.20

5.25

-4.06

Calmar ratioReturn relative to maximum drawdown

1.56

16.24

-14.68

Martin ratioReturn relative to average drawdown

3.72

32.22

-28.50

DRUG.AX vs. BBUS.AX - Sharpe Ratio Comparison

The current DRUG.AX Sharpe Ratio is 1.07, which is higher than the BBUS.AX Sharpe Ratio of 0.62. The chart below compares the historical Sharpe Ratios of DRUG.AX and BBUS.AX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

DRUG.AX vs. BBUS.AX - Drawdown Comparison

The maximum DRUG.AX drawdown since its inception was -26.79%, smaller than the maximum BBUS.AX drawdown of -77.93%. Use the drawdown chart below to compare losses from any high point for DRUG.AX and BBUS.AX.


Loading charts...

Drawdown Indicators


DRUG.AXBBUS.AXDifference

Max Drawdown

Largest peak-to-trough decline

-26.79%

-77.93%

+51.14%

Max Drawdown (1Y)

Largest decline over 1 year

-10.69%

-33.50%

+22.81%

Max Drawdown (3Y)

Largest decline over 3 years

-20.63%

-70.97%

+50.34%

Max Drawdown (5Y)

Largest decline over 5 years

-20.63%

Current Drawdown

Current decline from peak

-2.61%

-29.37%

+26.76%

Average Drawdown

Average peak-to-trough decline

-5.17%

-36.11%

+30.94%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.52%

17.20%

-12.68%

Volatility

DRUG.AX vs. BBUS.AX - Volatility Comparison

The current volatility for Betashares Global Healthcare Currency Hedged ETF (DRUG.AX) is 6.29%, while BetaShares US Equities Strong Bear Currency Hedged Complex ETF (BBUS.AX) has a volatility of 7.21%. This indicates that DRUG.AX experiences smaller price fluctuations and is considered to be less risky than BBUS.AX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


DRUG.AXBBUS.AXDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.29%

7.21%

-0.92%

Volatility (6M)

Calculated over the trailing 6-month period

11.71%

24.68%

-12.97%

Volatility (1Y)

Calculated over the trailing 1-year period

15.65%

881.65%

-866.00%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

14.95%

404.42%

-389.47%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

16.17%

404.42%

-388.25%

DRUG.AX vs. BBUS.AX - Expense Ratio Comparison

DRUG.AX has a 0.57% expense ratio, which is lower than BBUS.AX's 1.32% expense ratio.


Dividends

DRUG.AX vs. BBUS.AX - Dividend Comparison

DRUG.AX's dividend yield for the trailing twelve months is around 3.63%, while BBUS.AX has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018
BBUS.AX
BetaShares US Equities Strong Bear Currency Hedged Complex ETF
0.00%0.00%0.00%0.00%10.40%0.00%0.00%0.00%0.00%
DRUG.AX
Betashares Global Healthcare Currency Hedged ETF
3.63%0.00%2.84%0.00%0.00%4.49%0.62%0.28%3.37%

Frequently Asked Questions


DRUG.AX and BBUS.AX have a correlation of -0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, DRUG.AX is cheaper at 0.57% per year. The better choice depends on whether you care most about return, fees, risk, or income.

DRUG.AX is cheaper with a 0.57% expense ratio, compared with 1.32% for BBUS.AX.

DRUG.AX is categorized as Health & Biotech Equities, while BBUS.AX is Inverse Equities. DRUG.AX tracks Nasdaq Global ex-Australia Healthcare Hedged AUD Index, while BBUS.AX tracks S&P 500 Total Return Index. Their fees differ too: 0.57% for DRUG.AX and 1.32% for BBUS.AX.

Portfolio Optimizer

Find the right allocation for DRUG.AX and BBUS.AX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer